Nektar Therapeutics (NKTR) Stock Forecast & Price Target

Compare

1,562 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NKTR Analyst Ratings

Moderate Buy

7 Buy

1 Hold

1 Sell

Based on 9 analysts giving stock ratings to

Nektar

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NKTR Stock 12 Month Forecast

Average Price Target

$97.63

▲(90.98% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Nektar Therapeutics in the last 3 months. The average price target is $97.63 with a high forecast of $121.00 and a low forecast of $30.00. The average price target represents a 90.98% change from the last price of $51.12.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","65":"$65","122":"$122","36.5":"$36.5","93.5":"$93.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":121,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$121.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":97.63,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$97.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,36.5,65,93.5,122],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,61.11,65.71692307692308,70.32384615384615,74.93076923076923,79.53769230769231,84.14461538461538,88.75153846153846,93.35846153846154,97.96538461538461,102.57230769230769,107.17923076923077,111.78615384615384,116.39307692307692,{"y":121,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,61.11,63.919230769230765,66.72846153846153,69.53769230769231,72.34692307692308,75.15615384615384,77.96538461538461,80.77461538461537,83.58384615384615,86.39307692307692,89.20230769230768,92.01153846153846,94.82076923076923,{"y":97.63,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,61.11,58.716923076923074,56.323846153846155,53.93076923076923,51.53769230769231,49.144615384615385,46.75153846153846,44.35846153846154,41.965384615384615,39.57230769230769,37.17923076923077,34.786153846153844,32.39307692307692,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.7,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":13.95,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.41,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.95,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.59,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.85,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.93,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.11,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$121.00

Average Price Target$97.63

Lowest Price Target$30.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Samantha Semenkow

Citi

$102

Buy

99.53%

Upside

Reiterated

12/01/25

Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NASDAQ: NKTR) and Lexeo Therapeutics, Inc. (NASDAQ: LXEO)

Roger Song

Jefferies

$99→$121

Buy

136.70%

Upside

Reiterated

11/26/25

Jefferies Keeps Their Buy Rating on Nektar Therapeutics (NKTR)

Yasmeen Rahimi

Piper Sandler

$105

Buy

105.40%

Upside

Reiterated

11/25/25

Nektar Therapeutics (NKTR) Gets a Buy from Piper Sandler

Andy Hsieh

William Blair

―

Hold

―

Reiterated

11/17/25

Hold Rating Maintained Amid Uncertainty in Rezpeg Trial Outcomes and Ongoing Research

Julian Harrison

BTIG

$100

Buy

95.62%

Upside

Reiterated

11/14/25

Nektar Therapeutics: Buy Rating Driven by Promising REZPEG Data and Favorable Safety Profile in Alopecia Areata TreatmentWe hosted an investor call earlier this week with Dr. Nektar Therapeutics. Dr. King is a practicing dermatologist and pioneering alopecia specialist who was among the first to successfully treat alopecia areata (AA) with off-label JAK inhibitors over a decade ago and was a key investigator in clinical trials that led to the approvals of in AA. The discussion reviewed the current treatment landscape in AA, opportunities for improvement over SoC, expectations for REZOLVE-AA topline results expected next month, and upcoming NKTR catalysts. A replay can be accessed using this link. We summarize below the REZOLVE-AA data outcomes we are most interested in and what we think each should mean for NKTR shares.

Arthur He CFA

H.C. Wainwright

$6.5→$120

Buy

134.74%

Upside

Reiterated

11/11/25

H.C. Wainwright Reaffirms Their Buy Rating on Nektar Therapeutics (NKTR)

Jay Olson

Oppenheimer

$98

Buy

91.71%

Upside

Reiterated

11/10/25

Oppenheimer Reaffirms Their Buy Rating on Nektar Therapeutics (NKTR)

Jessica Fye

J.P. Morgan

$30

Sell

-41.31%

Downside

Reiterated

11/09/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Zymeworks (NASDAQ: ZYME), Sana Biotechnology (NASDAQ: SANA) and Nektar Therapeutics (NASDAQ: NKTR)

Mayank Mamtani

B. Riley Securities

$85→$105

Buy

105.40%

Upside

Reiterated

09/23/25

B. Riley Securities Sticks to Their Buy Rating for Nektar Therapeutics (NKTR)B.Riley analyst Mayank Mamtani raised the price target on Nektar Therapeutics (NASDAQ: NKTR) to $105.00 (from $85.00) while maintaining a Buy rating.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Samantha Semenkow

Citi

$102

Buy

99.53%

Upside

Reiterated

12/01/25

Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NASDAQ: NKTR) and Lexeo Therapeutics, Inc. (NASDAQ: LXEO)

Roger Song

Jefferies

$99→$121

Buy

136.70%

Upside

Reiterated

11/26/25

Jefferies Keeps Their Buy Rating on Nektar Therapeutics (NKTR)

Yasmeen Rahimi

Piper Sandler

$105

Buy

105.40%

Upside

Reiterated

11/25/25

Nektar Therapeutics (NKTR) Gets a Buy from Piper Sandler

Andy Hsieh

William Blair

―

Hold

―

Reiterated

11/17/25

Hold Rating Maintained Amid Uncertainty in Rezpeg Trial Outcomes and Ongoing Research

Julian Harrison

BTIG

$100

Buy

95.62%

Upside

Reiterated

11/14/25

Arthur He CFA

H.C. Wainwright

$6.5→$120

Buy

134.74%

Upside

Reiterated

11/11/25

H.C. Wainwright Reaffirms Their Buy Rating on Nektar Therapeutics (NKTR)

Jay Olson

Oppenheimer

$98

Buy

91.71%

Upside

Reiterated

11/10/25

Oppenheimer Reaffirms Their Buy Rating on Nektar Therapeutics (NKTR)

Jessica Fye

J.P. Morgan

$30

Sell

-41.31%

Downside

Reiterated

11/09/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Zymeworks (NASDAQ: ZYME), Sana Biotechnology (NASDAQ: SANA) and Nektar Therapeutics (NASDAQ: NKTR)

Mayank Mamtani

B. Riley Securities

$85→$105

Buy

105.40%

Upside

Reiterated

09/23/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Nektar Therapeutics

1 Month

xxx

Success Rate

10/21 ratings generated profit

Average Return

+0.95%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 47.62% of your transactions generating a profit, with an average return of +0.95% per trade.

3 Months

xxx

Success Rate

6/11 ratings generated profit

Average Return

+42.02%

reiterated a xxx

rating 29 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of +42.02% per trade.

1 Year

Julian HarrisonBTIG

Success Rate

10/11 ratings generated profit

Average Return

+196.07%

reiterated a buy rating 29 days ago

Copying Julian Harrison's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +196.07% per trade.

2 Years

xxx

Success Rate

10/11 ratings generated profit

Average Return

+196.47%

reiterated a xxx

rating 29 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 90.91% of your transactions generating a profit, with an average return of +196.47% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NKTR Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NKTR has received 10 Buy Ratings, 10 Hold Ratings, and 1 Sell Ratings. NKTR average Analyst price target in the past 3 months is 97.63.

Each month's total comprises the sum of three months' worth of ratings.

NKTR Financial Forecast

NKTR Earnings Forecast

Next quarter’s earnings estimate for NKTR is -$2.42 with a range of -$3.68 to -$1.66. The previous quarter’s EPS was -$1.87. NKTR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year NKTR has Performed in-line its overall industry.

NKTR Sales Forecast

Next quarter’s sales forecast for NKTR is $10.04M with a range of $6.90M to $15.81M. The previous quarter’s sales results were $11.79M. NKTR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year NKTR has Performed in-line its overall industry.

NKTR Stock Forecast FAQ

What is NKTR’s average 12-month price target, according to analysts?

Based on analyst ratings, Nektar Therapeutics’s 12-month average price target is 97.63.

What is NKTR’s upside potential, based on the analysts’ average price target?

Nektar Therapeutics has 90.98% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NKTR a Buy, Sell or Hold?

Nektar Therapeutics has a consensus rating of Moderate Buy which is based on 7 buy ratings, 1 hold ratings and 1 sell ratings.

What is Nektar Therapeutics’s price target?

The average price target for Nektar Therapeutics is 97.63. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $121.00 ,the lowest forecast is $30.00. The average price target represents 90.98% Increase from the current price of $51.12.

What do analysts say about Nektar Therapeutics?

Nektar Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of NKTR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Nektar Therapeutics (NKTR) Stock Forecast & Price Target

NKTR Analyst Ratings

NKTR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Nektar Therapeutics

NKTR Analyst Recommendation Trends

NKTR Financial Forecast

NKTR Earnings Forecast

NKTR Sales Forecast

NKTR Stock Forecast FAQ

Detailed List of Analyst Forecasts